Onyvax Ltd.
This article was originally published in Start Up
Executive Summary
Profile of company developing prostate cancer vaccine.
You may also be interested in...
Cancer Vaccines: European Immunotherapy Strategies
European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.
British Start-Ups
Many think that British biotech is a disaster waiting to happen. The four companies profiled in this issue are attempting to establish themselves as product-driven companies, run by professional managers.
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.